ANZCTR search results

This is a pilot study designed to gather data pertinent to the development of a large scale clinical trial, The study is an open label trial to be conducted over 12 weeks in otherwise healthy individuals. The study will compare baseline Comprehensive Osteoarthritis Test (COAT) measurements with end of study outcomes

The purpose of the study is to determine the efficacy of Evogen® Topical gel in relieving pain in participants with diagnosed osteoarthritis of the knee. The study hypothesies that the application of Evogen® Topical gel four times a day for 1 week will produce a 50% reduction in pain level.

Stem cell transplant recipients will receive an infusion of donor cells at least one month post transplant. Cells will have been stimulated in the laboratory so that they specifically recognise and kill parts of the viruses known as cytomegalovirus and adenovirus.

The primary purpose of this pilot study is to assess the clinical tolerability and safety of a new synthetic soft tissue implant material in the skin of healthy volunteers.

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic PE with or without symptomatic DVT (Einstein-PE). (11702b) This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT or PE who completed 6 or 12 months of treatment with rivaroxaban or VKA are eligible for this trial (Einstein-Extension study). (11899)

Use of chemotherapy and growth factors can affect the number of stem cells and cancer cells in blood circulation. Few studies have also shown that number of cancer cells can be of prognostic significance. There are no studies till date which have looked systematically at the influence of chemotherapy and growth factors on these cells. Hence present study was designed to answer these questions. The results of the study may not directly influence the way we treat the patients today but will definitely help us to understand the complex nature of breast cancer.

A randomised within-subjects design will be used to determine the effect of regular passive movements on the ankle. One ankle of each subject will receive 20 minutes of passive movements, five days a week for 6 months. The other ankle will not receive passive movements. The primary outcome measure is passive ankle dorsiflexion with the application of 17Nm torque. All measurements will be taken by blinded assessors.

The overall aim of this research is to test the efficacy of a brief, early cognitive-behavioural therapy (CBT) intervention in reducing anxiety [including cancer-related Posttraumatic Stress Disorder (PTSD)], and/or depression and improving the psychological well-being and quality of life for adult individuals newly diagnosed with head and neck cancer (HNC) who have been scheduled to receive radiation treatment. It is hypothesized that the CBT program (experimental condition) will help reduce anxiety and depressive symptoms both in the short- and longer-term (up to 12-months) following the completion of patients’ radiotherapy regimens, compared with a non-directive Supportive Counselling (SC) program (active control condition).

Recent work has reflected importance of estrogen in causation of lung cancer. This is especially true for female population and non smokers. Present trial is designed to test the hypothesis that decreasing estrogen along with inhibiting nutrient pathway in cancer cells could lead to disease control. There is preliminary data to suggest that the combination might be useful for other patients as well. The other highlight of the study is the oral treatment in contrast to other treatments which are injectable chemotherapy.

The purpose of this study is to demonstrate that the efficacy and safety of 20 mg once daily rivaroxaban in preventing thromboembolic events in subjects with atrial fibrillation not related to mitral valve stenosis. Subjects with moderate renal impairment at screening (defined as calculated creatinine clearance between 30 and 49 ml/min inclusive) will receive a dose adaptation to rivaroxaban 15 mg once daily.